TY - JOUR
T1 - Newly diagnosed lung cancer
T2 - Which molecular tests are needed for optimal treatment decision making?
AU - Ganti, Apar Kishor P
N1 - Publisher Copyright:
© 2019, UBM Medica Healthcare Publications. All rights reserved.
PY - 2018
Y1 - 2018
N2 - The management of advanced non–small-cell lung cancer (NSCLC) has changed dramatically over the past few years due to our expanded knowledge of the molecular basis of lung cancer (driver mutations and immune targets) and drugs that affect these pathways, namely targeted agents and checkpoint inhibitors. Consequently, it is important to test patients with newly diagnosed advanced NSCLC for potentially significant molecular abnormalities prior to the initiation of treatment. This requires close coordination between the surgical pathologist, the molecular pathologist, and the medical oncologist to ensure that the biopsy specimen is used judiciously to get all necessary information. In this article, I suggest an approach to the diagnostic evaluation of patients with newly diagnosed advanced NSCLC, in an attempt to identify the best treatment options for each.
AB - The management of advanced non–small-cell lung cancer (NSCLC) has changed dramatically over the past few years due to our expanded knowledge of the molecular basis of lung cancer (driver mutations and immune targets) and drugs that affect these pathways, namely targeted agents and checkpoint inhibitors. Consequently, it is important to test patients with newly diagnosed advanced NSCLC for potentially significant molecular abnormalities prior to the initiation of treatment. This requires close coordination between the surgical pathologist, the molecular pathologist, and the medical oncologist to ensure that the biopsy specimen is used judiciously to get all necessary information. In this article, I suggest an approach to the diagnostic evaluation of patients with newly diagnosed advanced NSCLC, in an attempt to identify the best treatment options for each.
UR - http://www.scopus.com/inward/record.url?scp=85053061850&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85053061850&partnerID=8YFLogxK
M3 - Article
C2 - 29940057
AN - SCOPUS:85053061850
SN - 0890-9091
VL - 32
SP - 276
EP - 280
JO - Oncology
JF - Oncology
IS - 6
ER -